drugset / Trial / NCT00410202

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202

Phase 3 Completed 629 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

Timeline

Start
2008-03
Primary completion
2011-01
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adefovir Unknown 10 mg Oral
Comparator Entecavir Small molecule 1 mg Oral
Comparator Lamivudine Other / unclassified 100 mg Oral
Comparator Tenofovir Small molecule 300 mg Oral